Sonatherm® Laparoscopic HIFU device used to demonstrate thermal ablation at hands-on lab

CHARLOTTE, NC -- SonaCare Medical, a leading manufacturer of medical High Intensity Focused Ultrasound (HIFU) devices, recently participated in the American Urology Association's (AUA) surgical summit "Small Renal Mass 360°." Key opinion leaders in urology presented on the latest diagnostic and therapeutic advances related to small renal masses while attendees had the opportunity to evaluate and learn about different ablative technologies in hands-on labs. Attendees at the Los Angeles, CA lab, under direction of course director Inderbir Gill, MD, successfully used the Sonatherm® (HIFU) device to laparoscopically ablate porcine kidney tissue as well as the bladder wall. Dr. Gill had previously performed the first outpatient renal ablation with Sonatherm®.

Dr. David Schulsinger spearheads pilot study for ablation of renal cell carcinoma with SonaCare Medical's Sonatherm®Laparoscopic Soft Tissue HIFU Surgical Ablation Device

Charlotte, NC. October 28, 2014 -- SonaCare Medical, manufacturer of High Intensity Focused Ultrasound (HIFU) ablative devices, announces ongoing progress at Stony Brook University in Stony Brook, NY where Dr. David Schulsinger and his team are conducting the first North American Institutional Review Board (IRB) approved treat and resect study of kidney cancer in humans with SonaCare's Sonatherm® laparoscopic soft tissue HIFU Surgical Ablation Device.

"Beyond being a true visionary, Mark has the experience to lead SonaCare both strategically and on a day-to-day basis."

CHARLOTTE, NC. -- SonaCare Medical, LLC, leader in minimally invasive high intensity focused ultrasound (HIFU) technology, announced that its Board of Directors has appointed Dr. Mark Carol, M.D. as Chief Executive Officer, President and member of the Board effective immediately. In his new role Dr. Carol will take-on expanded responsibilities within the company, including further developing the company's HIFU technology, as well as overseeing commercialization, manufacturing and finance. 

FRIDAY, OCTOBER 3, 2014 CHARLOTTE, NC.  SonaCare Medical, LLC, a leader in minimally invasive high intensity focused ultrasound (HIFU) technology, announced that the Gastroenterology and Urology Device Panel met on Wednesday October 1st with representatives from the FDA and SonaCare Medical to review and vote on recommendations for the interim analysis of SonaCare Medical's Sonablate® 450's safety, efficacy, and risk/benefits ratio for the treatment of biopsy proven recurrent prostate cancer, stage T1c-T2, in patients who have failed primary external beam radiation therapy and have a PSA≤10 ng/mL.

Fast paced sales growth sets a new company record and underscores the continued worldwide acceleration in demand for SonaCare's unique HIFU platform technology

CHARLOTTE, NC -- SonaCare Medical, LLC, the global leader in high intensity focused ultrasound (HIFU), announced record-setting sales of 15 HIFU devices over the past twelve months pointing to a steady worldwide surge in demand for the company's ablation technology. 

SonaCare Medical, LLC, the global leader in urologic high intensity focused ultrasound (HIFU), is proud to provide platinum support for the upcoming 7th International Symposium on Focal Therapy and Imaging in Prostate & Kidney Cancer. This year's symposium takes place at the Langham Huntington Resort in Pasadena, CA from August 21st to 23rd and includes faculty members from seven countries who have put together a comprehensive scientific program including multiple HIFU sessions.

HIFU company


10130 Perimeter Pkwy, Suite 250
      Charlotte, NC 28216

(888) 874-4384

Mon - Fri: 9:00 - 5:00

Latest News

10 April 2018

Over 120 urologists gather at Imperial College London to learn new diagnostic techniques and minimally invasive focal approaches for treating prostate cancer.

05 April 2018

CHARLOTTE, NC (PR NEWSWIRE) APRIL 05, 2018 – SonaCare Medical, the leading developer and manufacturer of high intensity focused ultrasound (HIFU) technologies, announces the enrollment of over 100 patients from...